Vunakizumab治疗活动性银屑病关节炎的2期随机对照研究
这项多中心、随机、双盲、安慰剂对照2期试验纳入活动性银屑病关节炎(PsA)患者,按1:1:1随机接受Vunakizumab 120 mg(n=38)、240 mg(n=37)或安慰剂(n=37)皮下注射。第12周时,120 mg组(47.4%)和240 mg组(59.5%)的ACR20应答率均高于安慰剂组(21.6%,P分别为0.02和0.001),且疗效持续至24周,安全性可接受。
要点
- Vunakizumab 120 mg和240 mg组第12周ACR20应答率均显著优于安慰剂。
- 第12周后安慰剂组转为Vunakizumab治疗,疗效持续至24周。
- 12周核心治疗期内各组TEAE发生率相近,未发生严重TEAE。
核心结论
- Vunakizumab在活动性PsA患者中疗效优于安慰剂,耐受性良好且安全性可接受。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照2期试验,纳入18-75岁确诊活动性PsA患者。
- 患者按1:1:1随机接受皮下Vunakizumab 120 mg(n=38)、240 mg(n=37)或安慰剂(n=37),于第0、2、4、8周给药。
- 第12周时安慰剂组按1:1重新随机转为Vunakizumab 120 mg或240 mg至第20周,Vunakizumab组继续治疗。
- 主要终点为第12周ACR20应答率。
主要发现
- 第12周ACR20应答率:Vunakizumab 120 mg组47.4%,240 mg组59.5%,安慰剂组21.6%(P=0.02和P=0.001)。
- 疗效持续至24周,第12周后由安慰剂转为Vunakizumab的患者也观察到改善。
- 12周核心治疗期内TEAE发生率:Vunakizumab 120 mg组73.7%,240 mg组64.9%,安慰剂组70.3%,未发生严重TEAE。
临床怎么用
- Vunakizumab作为靶向IL-17A的人源化单克隆抗体,2期结果支持推进3期研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Current PsA therapies, from conventional agents (e.g. MTX) to targeted biologics (e.g. TNF and IL-17 inhibitors), demonstrate distinct therapeutic profiles. Vunakizumab (SHR-1314) is a novel humanized mAb targeting IL-17A. The phase 2 trial evaluated the efficacy and safety of vunakizumab in patients with active PsA. METHODS: Patients aged 18-75 years with a confirmed diagnosis of active PsA were randomized (1:1:1) to receive either s.c. vunakizumab 120 mg (n = 38), vunakizumab 240 mg (n = 37) or placebo (n = 37) at weeks 0, 2, 4 and 8. At week 12, patients on placebo were switched to vunakizumab (1:1 re-randomized to 120 mg or 240 mg through week 20), while vunakizumab groups continued treatment. The primary endpoint was ACR 20% improvement (ACR20) response rate at week 12. RESULTS: At week 12, ACR20 response rates were higher in the vunakizumab 120 mg (47.4%) or 240 mg (59.5%) groups vs placebo group (21.6%; P = 0.02 and P = 0.001, respectively). In addition, improvements were sustained through 24 weeks and were noted in patients who switched from placebo after week 12. Treatment-emergent adverse events (TEAEs) incidence exhibited analogous frequencies between vunakizumab [73.7% (120 mg), 64.9% (240 mg)] and placebo (70.3%) during the 12-week core treatment period, and no severe TEAEs occurred. CONCLUSIONS: Vunakizumab demonstrated superior efficacy to placebo and was well tolerated with an acceptable safety profile in patients with active PsA. The findings support proceeding to a phase 3 study. TRIAL REGISTRATION: ClinicalTrials.gov, www. clinicaltrials.gov, NCT05055934.
引用
- Xue Y, Sun L, Zhang N, et al. Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 study. Rheumatology (Oxford). 2026. PMID: 41632483. doi:10.1093/rheumatology/keag060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。